Inclusion Criteria:

• Subjects received a kidney transplant in the prior 3 months.
• Subjects receiving maintenance therapy consisting of tacrolimus, mycophenolate sodium or mycophenolate mofetil, and optionally corticosteroids, at the time of enrollment.
• Subjects received induction therapy comprising IL2 receptor antagonist or thymoglobulin, or received no induction therapy.
• 18 years of age or older at time of signing informed consent.
• Able to read, understand and provide written informed consent, and willing and able to comply with the study requirements. If the subject is unable to sign the informed consent, a legally authorized representative (LAR) can consent on behalf of the subject.
• Subjects are at the site standard-of-care MPA dosage

Exclusion Criteria:

• Concurrent multiple solid organ or tissue transplants.
• History of a previous organ transplant (aside from present kidney transplant), or cellular transplant.
• DSA Positive according to local protocol, including either pre-transplant DSA positivity and de novo DSA positivity.
• Any prior dd-cfDNA results ≥1.0% or ≥78cp/mL after 28 days post-transplant.
• ABO Incompatible donor.
• A serious medical condition that may adversely affect ability to participate in the study (e.g, current diagnosis of cancer).
• Pregnancy.
• Received any induction therapy other than IL2 receptor antagonist or thymoglobulin.
• Receiving any maintenance immunosuppression other than tacrolimus, mycophenolate sodium or mycophenolate mofetil, and prednisone.
• Currently undergoing regular dialysis.
• Considered high-risk at the time of enrollment, as per the treating physician.
• Planned or ongoing use of other commercially available or investigational dd-cfDNA or blood-based gene expression profile assays for rejection surveillance, through randomization.